Morbidity and mortality among patients with breast cancer receiving anticancer treatment before and during the COVID‑19 pandemic: A single tertiary center experience
- Marwan Al-Hajeili
- Reem Ujaimi
- Omar Iskanderani
- Nora Trabulsi
- Somayah Bawazeer
Affiliations: Department of Internal Medicine, Faculty of Medicine, King Abdulaziz University, Jeddah 22254, Kingdom of Saudi Arabia, Department of Radiology, Faculty of Medicine, King Abdulaziz University, Jeddah 22254, Kingdom of Saudi Arabia, Department of Surgery, Faculty of Medicine, King Abdulaziz University, Jeddah 22254, Kingdom of Saudi Arabia, Department of Community Medicine, Faculty of Medicine, King Abdulaziz University, Jeddah 22254, Kingdom of Saudi Arabia
- Published online on: November 1, 2022 https://doi.org/10.3892/ol.2022.13574
Copyright: © Al-Hajeili
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Breast cancer is the most common cancer type in women in Saudi Arabia (SA). Globally, cancer treatment has been affected by the recent COVID‑19 pandemic. The present retrospective study reviews the 30‑day morbidity and mortality rates of patients with breast cancer receiving anticancer systemic treatment before (group1) and during the peak of the COVID‑19 (group 2) pandemic at a tertiary center, King Abdulaziz University Hospital (Jeddah, SA). There were no differences between the two groups regarding sex, age, breast cancer stage distribution, intention to treat or class of anticancer treatment received. Patients treated during the peak pandemic period received delayed treatment. No statistically significant difference was observed in the 30‑day morbidity or mortality rates, although there was a trend towards higher rates of morbidity among patients treated during the peak of the pandemic period. In group 2, only 2.3% of the patients tested positive for COVID‑19, and there was no significant difference in the 30‑day morbidity and mortality rates between COVID‑positive and COVID‑negative patients receiving anticancer treatment. Individuals with breast cancer are a vulnerable group of patients that should be treated with special care during pandemics or other crises that affect the health care system.